Clostridioides Difficile Infection Recurrence Clinical Trials
3 recruiting trials for Clostridioides Difficile Infection Recurrence. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Clostridioides Difficile Infection Recurrence clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 3 is the largest group at 50% (1 studies); the largest phase groups are Phase 3: 1, Phase 2 / Phase 3: 1.
Research is led by Vedanta Biosciences, Inc. (1), Bactolife A/S (1), McGill University Health Centre/Research Institute of the McGill University Health Centre (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Placebo (biological, 2 trials), followed by VE303, Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment..
Track Clostridioides Difficile Infection Recurrence trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive...
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of this study is to map...
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Clostridioides Difficile Infection Recurrence, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Clostridioides Difficile Infection Recurrence, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Clostridioides Difficile Infection Recurrence, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.